Key Points Wall Street analysts have raised price targets on Abbott, citing accelerating growth in its Medical Devices segment. Abbott's diabetes, electrophysiology, and new Exact Sciences cancer-screening businesses are driving stronger sales and earnings. Abbott's future dividend increases depend on turning growth investments into stronger cash flow. 10 stocks we like better than Abbott Laboratories › A Dividend King is a company that's raised its dividend for at least 50 years consecutively. Abbott Laboratories (NYSE: ABT) , for example, is one such company, having raised its dividend for 54 straight years. But that's not really why Wall Street is bullish on the stock.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.
